Patent · US Active

Dual targeting of TAFI and PAI-1

US10239953B2 · kind B2 · utility

0Cited by

0References

19Claims

0Family size

Assignees

Katholieke Universiteit Leuven · BE
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
UNIVERSITE DE CAEN BASSE NORMANDIE · FR
CENTRE HOSPITALIER ET UNIVERSITAIRE DE BREST · FR

Inventors

Paul Declerck · Palatine, US
Simon De Meyer · Leuven, BE
Nick Geukens · Leuven, BE
Ann Gils · Leuven, BE
Marina Rubio · Caen, FR
Denis VIVIEN · Caen, FR
Tine Wyseure · Leuven, BE

Key dates

Filing date	Feb 9, 2015
Grant date	Mar 26, 2019
Priority date	—
Expiry date	May 18, 2035

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/22
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein is a bispecific inhibitor for use in treating thrombotic disorders, such as acute thrombotic disorders like stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies targeting TAFI and PAI-1, and shows efficacy in the presence or the absence of plasminogen activators such as tissue-type plasminogen activator (tPA).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.